Skip to main content

Prosthetic Infection and Biofilm Protocols

Prosthetic infections in urology — inflatable penile prosthesis (IPP), artificial urinary sphincter (AUS), and pelvic mesh — are governed by a pharmacology fundamentally different from soft-tissue or urinary-tract infection. Bacteria and fungi adherent to synthetic surfaces form biofilms that confer antibiotic tolerance orders of magnitude greater than the planktonic state, rendering standard MIC-based antimicrobial therapy inadequate and making infection prevention far more important than infection treatment. A clinically infected implant usually requires surgical source control; asymptomatic colonization is not by itself an indication for explantation.[1][2]

This article is the pharmacology-oriented synthesis of protocols that sit at the interface of perioperative antimicrobial prophylaxis, dipping / irrigation solutions, and device-specific chemistry. For the surgical-technique deep-dive on IPP infection, see Penile implants — infection; for the general perioperative framework, see Perioperative antibiotic prophylaxis.

Biofilm biology — why prosthetic infections are different​

Within hours of implantation, planktonic bacteria and fungi adherent to a synthetic surface secrete an extracellular polymeric matrix that:

  • Reduces antibiotic penetration to the encased cell population
  • Induces a low-metabolic-activity subpopulation (persister cells) refractory to cell-wall-active and protein-synthesis-targeting agents
  • Facilitates horizontal gene transfer of resistance determinants
  • Is disrupted mechanically more effectively than chemically — which is the rationale for jet-irrigation approaches

Standard susceptibility testing alone cannot predict eradication of an established biofilm; cultures still guide antimicrobial treatment alongside source control. Prevention — eliminating contamination at the moment of implantation — carries far more leverage than post-infection treatment does.[1][2]

The contemporary microbial landscape​

Contemporary device-infection microbiology has shifted meaningfully over two decades. The Gross 2017 multicenter IPP-infection cultures analysis defined the current spectrum:[3]

Organism classApproximate share of modern IPP infections
Coagulase-negative StaphylococcusHistorically dominant; now reduced by antibiotic-impregnated coatings
MRSA~10%
Gram-negative organismsIncreasing share
Candida spp. (albicans, glabrata)Up to 11%
PolymicrobialCommon in revision / salvage

A dedicated retrospective series found fungal involvement in 26/217 infected devices (12%), often in patients with diabetes or excess weight; this is not the incidence among all implants.[29] A broader review describes this evolving microbiology.[4] The antibiotic regimens recommended by the original 2008 AUA BPS — extrapolated from orthopedic and general-surgery literature — target the older microbial spectrum and are increasingly mismatched to the organisms that actually cause modern device infections.

IPP prophylaxis — the PUMP reassessment​

The Prosthetic Urology Multi-Institutional Partnership (PUMP) has produced the most consequential challenge to standing AUA IPP prophylaxis recommendations. These are retrospective datasets, not randomized comparisons:

  • Barham 2023 (J Urol, PUMP, 4,161 primary IPPs) — vancomycin + gentamicin alone was associated with a 2.7-fold higher infection risk than nonstandard regimens (HR 2.7; 95% CI 1.4–5.4; p = 0.004).[5]
  • Abou Chawareb 2025 (5,261 patients, 16 centers) — IV antifungal use was independently associated with significantly lower infection risk (OR 0.22; p < 0.001). Postoperative oral antibiotics and IV prophylaxis >24 h showed no protective effect. Diabetes (OR 1.68) and prior IPP infection (OR 4.67) were the dominant patient-level risk factors.[6]
  • Rezaee 2020 (diabetic subgroup) — AUA-adherent prophylaxis yielded 5.6% infection rates vs 1.9% for nonstandard regimens in diabetic primary IPPs. Comparator regimens included vancomycin-gentamicin-fluoroquinolone, clindamycin-fluoroquinolone, and vancomycin-fluoroquinolone combinations.[7]

Practice-pattern gap: Brant 2023 national-cohort data show a 42% relative increase in AUA-adherent vancomycin-plus-gentamicin regimen use after the BPS publication — a practice pattern that should be considered alongside, rather than invalidated by, the observational comparisons.[8] The 2025 Sex Med Rev from the 5th International Consultation on Sexual Medicine is the current expert-consensus counterpoint pending formal BPS revision.[9]

Applying the prophylaxis evidence​

Use the institutional implant protocol, local susceptibility data and patient-specific renal function/allergies to select perioperative coverage. The PUMP antifungal association (OR 0.22 = 78% lower adjusted odds) supports considering an antifungal strategy; it does not establish a universal vancomycin/gram-negative-agent/fluconazole regimen, dose, or causal effect.[6]

Administer prophylaxis before incision, allowing time for a vancomycin infusion when indicated, and avoid routine extended courses after an uncomplicated implantation. The lack of a protective association with postoperative oral antibiotics is consistent with stewardship; it is not a reason to stop treatment of an established infection or infected salvage case.[6][10]

Adoption patterns — SMSNA/SUPS/GURS 2025 survey — antifungal use: 25.9% primary, 72.3% diabetic, 65.2% salvage, 48.2% revision cases.[11] Addition of antifungal to hydrophilic-dip solutions preserved antibacterial activity for the studied mixtures on bench testing; this does not prove clinical infection prevention.[12]

See Antifungals for the detailed case for fluconazole in IPP surgery.

Device-specific dipping — InhibiZone vs hydrophilic Titan​

Dipping / irrigation chemistry is fundamentally device-specific. Confusing the two is a common — and consequential — error.

AMS 700 InhibiZone (Boston Scientific)​

  • Factory-applied rifampin + minocycline antibiotic surface treatment; do not describe this as an inert covalent coating
  • Do not soak InhibiZone components: antibiotics can diffuse into the solution. Follow the component IFU for handling; a brief rinse immediately before placement is different from prolonged immersion.[27]
  • Select field irrigation separately from device preparation using the operative protocol; see the limitations of CHG evidence below
  • Carson 2004 registration data: infection 1.61% → 0.68% at 6 months; Carson 2011 confirmed durability out to 7.7 y[13][14]

Coloplast Titan (hydrophilic)​

  • Polyvinylpyrrolidone (PVP) surface that absorbs surgeon-applied antibiotic solution
  • Use the manufacturer's hydrophilic-device preparation instructions and a compatible aqueous solution; dipping does not replace systemic prophylaxis or aseptic technique.[28]
  • Vancomycin + gentamicin was associated with fewer infections than other dips pooled in Towe 2020 (1.4% vs 6.4%; 468 diabetic Titan recipients with dip data). This retrospective comparison does not establish superiority of a particular concentration or a universal recipe[15]
  • Selected antifungal-containing mixtures retained antibacterial activity in vitro; systemic antifungal findings cannot be assumed to apply to dipping[12]
  • Wolter & Hellstrom 2004 registration data: infection 2.07% → 1.06% at 1 year; Serefoglu 2012 confirmed durability out to 11 y[16][17]

Irrisept (0.05% chlorhexidine gluconate) — the 2026 device-specific pivot​

Irrisept contains 0.05% CHG in sterile water and is cleared for mechanical cleansing and removal of wound debris, including microorganisms. The label calls for approximately one minute of contact followed by saline rinsing, and prohibits use with CHG allergy. Clearance for wound cleansing does not establish infection prevention or compatibility with every implant; follow both product labels.[30]

Device-specific outcomes — the critical point​

Ivan 2026 reported two retrospective multicenter cohorts; they raise device-specific concerns but are not a randomized comparison or a consensus guideline:

DeviceCHG vs antibiotic-only irrigationPractical
AMS 700 InhibiZone (n = 761)No statistically detected association — 1.9% CHG vs 2.0% comparator (p = 0.9)[19]Does not prove equivalence or safety; CHG follow-up was shorter and infection events were uncommon
Coloplast Titan (hydrophilic, n = 2,150)Higher infection — 4.6% CHG vs 2.1% antibiotic (p < 0.001); 12% in CHG revision subgroup[20]Use caution and favor a compatible antimicrobial protocol pending prospective evidence; mechanism is not established by this cohort

Laboratory evidence is mixed and device dependent. Simhal 2024 found greater bacterial reduction with vancomycin/gentamicin than CHG on hydrophilic discs; both saline and CHG irrigation could remove the adsorbed dip in that model. This offers a possible mechanism, not proof of why patients developed infections.[21] Karpman 2023 also studied Titan, finding microbial reductions under a different in-vitro protocol; it was not an InhibiZone experiment.[18] Im 2024 found preserved InhibiZone antimicrobial activity after CHG exposure in vitro.[23]

Helo 2025 independently reported a concerning before/after Titan cohort (13/377 infections with CHG vs 0/320 with antibiotic dip/irrigation). Changes over time and patient selection remain potential confounders.[22]

Solutions to avoid​

  • High-concentration povidone-iodine implant irrigation — Manka 2020 (217 patients, single surgeon) associated 5% Betadine with higher adjusted infection odds (OR 9.3) than vancomycin/gentamicin. This retrospective result supports caution with that protocol; it does not prohibit every dilute, sterile povidone-iodine wound application.[24]
  • Hydrogen peroxide — tissue cytotoxicity, impaired wound healing, documented risk of corporal air embolism. Dropped from the modern Mulcahy salvage protocol.
  • Bacitracin-polymyxin or TMP-SMX-gentamicin dips on hydrophilic devices — Towe 2020 favored vancomycin/gentamicin over other dips pooled, with the limitations noted above.[15]
  • 0.05% CHG on hydrophilic Titan devices — Ivan 2026 data as above.[20]

AUS prophylaxis​

Use a procedure-specific institutional prophylaxis protocol; IPP antifungal associations cannot be assumed to apply to AUS. Sun 2023 (n = 9,775) associated guideline-adherent prophylaxis with fewer overall complications/revisions, but did not detect a reduction in infection specifically (OR 0.89; 95% CI 0.68–1.17). This does not prove a particular regimen is inadequate.[25]

IDSA suggests not screening for or treating asymptomatic bacteriuria solely before AUS or penile-prosthesis implantation (weak, very-low-quality evidence), while still giving standard perioperative prophylaxis. Active UTI, systemic infection, and planned urinary mucosal trauma are separate situations.[26] Follow the actual AMS 800 InhibiZone handling precautions rather than borrowing a Titan dipping protocol.[27]

Mesh and sacrocolpopexy​

Select antibiotic prophylaxis by the operation and any concomitant vaginal or bowel entry. Crossing the peritoneum alone is not an indication for metronidazole. Use the gynecologic or bowel-surgery protocol as applicable, including weight-based dosing and redosing for long operations or major blood loss.[31]

For vaginal preparation, povidone-iodine is a labeled option; ACOG permits selected low-alcohol CHG formulations off label. High-alcohol skin preparations must not be substituted for vaginal preparations. Follow formulation-specific instructions and the institutional vaginal-preparation protocol.[31] IPP studies do not establish routine antifungal prophylaxis for slings or prolapse mesh.

Salvage — the Mulcahy washout​

Modified-Mulcahy protocol (for suspected or confirmed IPP infection):

  1. Explant all prosthesis components
  2. Sequential antiseptic washes — avoid hydrogen peroxide and excess povidone-iodine in modern practice
  3. Change all gloves and instruments between explant and reimplant phases
  4. Re-prep and re-drape the field
  5. Replace with a new antibiotic-coated implant

Contemporary 2026 considerations​

  • Obtain appropriate cultures during infected explant/salvage to guide treatment. Molecular testing is not an established routine requirement and detection does not necessarily establish causation
  • Fresh antibiotic-coated device used even in presumed non-infectious revisions
  • Consider fungal coverage according to infection severity, host risk, prior cultures and local protocol; prophylaxis cohorts do not define treatment duration for infected salvage[4][6]
  • 0.05% CHG specifically avoided in revisions involving hydrophilic devices given the 12% infection rate in this subgroup in Ivan 2026[20]
  • Prior IPP infection is the single largest patient-level risk factor (OR 4.67 in Abou Chawareb 2025)[6]

Evidence Summary​

QuestionEvidence and interpretation
Systemic IPP prophylaxisPUMP retrospective cohorts: important associations, not Level 1 randomized treatment effects.[5][6]
Postoperative prophylactic antibioticsNo protective association in the cited cohorts; distinguish prophylaxis from treatment after infected salvage.[6][10]
Antibiotic surface treatment/dippingManufacturer instructions determine preparation; observational infection comparisons do not validate arbitrary mixing recipes.[13][14][15][16][17]
CHG and IPPConcerning hydrophilic-device cohorts; absence of an association on antibiotic-impregnated devices is not proof of safety.[19][20][22]
Laboratory compatibilityBench findings depend on coating, organisms and assay; they cannot establish clinical infection prevention.[18][21][23]

Clinical Positioning​

  • Keep a documented local prophylaxis and device-preparation protocol, reconciled with current IFUs and stewardship review.
  • Do not soak InhibiZone components or transfer a hydrophilic-device recipe to them. Confirm the device and coating before opening solutions.[27][28]
  • Consider recent antifungal and CHG evidence without calling observational findings causal or extending them automatically to AUS/mesh.
  • Established implant infection needs a source-control and culture-directed treatment plan; it is not covered by a routine prophylaxis stop rule.
  • Track local infections, organisms, device type and regimen so changes can be assessed against actual outcomes.

See Also​

References​

1. Wilson SK, Costerton JW. "Biofilm and penile prosthesis infections in the era of coated implants: a review." J Sex Med. 2012;9(1):44–53. doi:10.1111/j.1743-6109.2011.02428.x

2. Eid JF. "Penile implant: review of a 'no-touch' technique." Sex Med Rev. 2016;4(3):294–300. doi:10.1016/j.sxmr.2016.01.002

3. Gross MS, Phillips EA, Carrasquillo RJ, et al. "Multicenter investigation of the microorganisms involved in penile prosthesis infection: an analysis of the efficacy of the AUA and EAU guidelines for penile prosthesis prophylaxis." J Sex Med. 2017;14(3):455–463. doi:10.1016/j.jsxm.2017.01.007

4. Natsos A, Tatanis V, Lekkou A, et al. "Unveiling the hidden perils: a comprehensive review of fungal infections in inflatable penile prosthesis surgery." J Pers Med. 2024;14(6):644. doi:10.3390/jpm14060644

5. Barham DW, Pyrgidis N, Gross MS, et al. "AUA-recommended antibiotic prophylaxis for primary penile implantation results in a higher, not lower, risk for postoperative infection: a multicenter analysis." J Urol. 2023;209(2):399–409. doi:10.1097/JU.0000000000003071

6. Abou Chawareb E, Hammad MAM, Azad B, et al. "Perioperative antimicrobial strategies in inflatable penile prosthesis surgery: associations between antifungals, oral antibiotics, and intravenous antibiotic duration, and infection outcomes." J Urol. 2025;214(6):642–653. doi:10.1097/JU.0000000000004716

7. Rezaee ME, Towe M, Osman MM, et al. "A multicenter investigation examining American Urological Association recommended antibiotic prophylaxis vs nonstandard prophylaxis in preventing device infections in penile prosthesis surgery in diabetic patients." J Urol. 2020;204(5):969–975. doi:10.1097/JU.0000000000001158

8. Brant A, Lewicki P, Punjani N, et al. "Trends in antimicrobial prophylaxis for inflatable penile prosthesis surgery from a large national cohort." Urology. 2023;172:131–137. doi:10.1016/j.urology.2022.11.010

9. Köhler T, Munarriz R, Parker J, et al. "Penile prosthesis for erectile dysfunction: recommendations from the 5th International Consultation on Sexual Medicine." Sex Med Rev. 2025;13(2):144–171. doi:10.1093/sxmrev/qeaf001

10. Dropkin BM, Chisholm LP, Dallmer JD, et al. "Penile prosthesis insertion in the era of antibiotic stewardship — are postoperative antibiotics necessary?" J Urol. 2020;203(3):611–614. doi:10.1097/JU.0000000000000578

11. Abou Chawareb E, Barham DW, Hammad MAM, et al. "Multicenter examination of contemporary penile prosthesis surgery infection prophylaxis practices." J Sex Med. 2025;22(8):1531–1533. doi:10.1093/jsxmed/qdaf145

12. Im B, Giordano A, Winslow A, Hickok N, Chung P. "Addition of antifungal agents to antibiotic solutions does not diminish the antibacterial properties of penile prosthesis hydrophilic surface dips." J Sex Med. 2026;23(2). doi:10.1093/jsxmed/qdaf372

13. Carson CC. "Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants." J Urol. 2004;171(4):1611–1614. doi:10.1097/01.ju.0000118245.66976.e1

14. Carson CC III, Mulcahy JJ, Harsch MR. "Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of follow-up." J Urol. 2011;185(2):614–618. doi:10.1016/j.juro.2010.09.094

15. Towe M, Huynh LM, Osman MM, et al. "Impact of antimicrobial dipping solutions on postoperative infection rates in patients with diabetes undergoing primary insertion of a Coloplast Titan inflatable penile prosthesis." J Sex Med. 2020;17(10):2077–2083. doi:10.1016/j.jsxm.2020.07.009

16. Wolter CE, Hellstrom WJG. "The hydrophilic-coated inflatable penile prosthesis: 1-year experience." J Sex Med. 2004;1(2):221–224. doi:10.1111/j.1743-6109.2004.04032.x

17. Serefoglu EC, Mandava SH, Gokce A, et al. "Long-term revision rate due to infection in hydrophilic-coated inflatable penile prostheses: 11-year follow-up." J Sex Med. 2012;9(8):2182–2186. doi:10.1111/j.1743-6109.2012.02830.x

18. Karpman E, Griggs R, Twomey C, Henry GD. "Dipping Titan implants in Irrisept solution (0.05% chlorhexidine gluconate) and exposure to various aerobic, anaerobic, and fungal species." J Sex Med. 2023;20(7):1025–1031. doi:10.1093/jsxmed/qdad055

19. Ivan SJ, Abou Chawareb E, Hammad M, et al. "0.05% chlorhexidine gluconate is not associated with infection in antibiotic-impregnated inflatable penile prosthesis surgery: results from a large multi-institutional collaborative." J Sex Med. 2026;23(1):qdaf368. doi:10.1093/jsxmed/qdaf368

20. Ivan SJ, Abou Chawareb E, Hammad M, et al. "Intraoperative 0.05% chlorhexidine gluconate utilization is associated with an increased incidence of infection in hydrophilic inflatable penile prosthesis surgery: a multi-institutional cohort study." J Urol. 2026;215(4):460–471. doi:10.1097/JU.0000000000004853

21. Simhal R, Im BH, Shah S, et al. "Antibiotic dip and irrigation solutions confer increased antimicrobial efficacy of inflatable penile prosthesis hydrophilic surfaces compared with 0.05% chlorhexidine gluconate." J Sex Med. 2024;21:816–822. doi:10.1093/jsxmed/qdae073

22. Helo S, Bonakdar Hashemi M, Ziegelmann MJ, et al. "Chlorhexidine gluconate application, diabetes, revision surgery, and extended operative time increase risk for penile implant infection." J Sex Med. 2025;22:508–516. doi:10.1093/jsxmed/qdaf009

23. Im BH, Giordano A, Shah S, et al. "Minocycline-rifampin-impregnated penile prosthesis surfaces retain antimicrobial activity following irrigation with 0.05% chlorhexidine gluconate and antibiotic solutions." J Sex Med. 2024;21:823–826. doi:10.1093/jsxmed/qdae093

24. Manka MG, Yang D, Andrews J, et al. "Intraoperative use of Betadine irrigation is associated with a 9-fold increased likelihood of penile prosthesis infection: results from a retrospective case-control study." Sex Med. 2020;8:422–427. doi:10.1016/j.esxm.2020.05.010

25. Sun HH, Callegari M, Zhou E, et al. "Trends over 20 years of antimicrobial prophylaxis for artificial urinary sphincter surgery." Neurourol Urodyn. 2023;42(6):1421–1430. doi:10.1002/nau.25206

26. Nicolle LE, Gupta K, Bradley SF, et al. "Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America." Clin Infect Dis. 2019;68(10):e83–e110. doi:10.1093/cid/ciy1121

27. Boston Scientific. AMS 700 operating-room manual and AMS 800 safety/handling information. Accessed September 12, 2026.

28. Coloplast. Titan penile implants: hydrophilic coating and product information. Accessed September 12, 2026; follow the packaged model-specific IFU.

29. Gross MS, Reinstatler L, Henry GD, et al. "Multicenter investigation of fungal infections of inflatable penile prostheses." J Sex Med. 2019;16:1100–1105. doi:10.1016/j.jsxm.2019.05.003

30. Irrimax. Irrisept product indications and instructions. Accessed September 12, 2026.

31. ACOG. Perioperative pathways: enhanced recovery after surgery. Antimicrobial prophylaxis and vaginal preparation; accessed September 12, 2026.